The survey also showed that 9 out of 10 physicians (91%) who prescribe MabThera (rituximab) for the treatment of this increasingly common form of cancer, said there is a significant improvement in their patients' quality of life.
The survey found that physicians are increasingly prescribing MabThera for the treatment of NHL. Of those who have prescribed MabThera, 92% said their usage increased over the last three years and, of these, over half (62%) said their increased prescribing of MabThera in combination with chemotherapy is based on proven efficacy. This reflects clinical studies that have demonstrated that MabThera can increase survival when combined with conventional chemotherapy without additional toxicity, or compromising tolerability.1
Approximately 1.5 million people around the world are affected by NHL, which is the third fastest growing form of cancer after skin melanoma and lung cancer.2
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-oriented healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche's innovative products and services address needs for the prevention, diagnosis and treatment of diseases, thus enhancing well-being and quality of life.
Roche is a world leader in oncology. Its franchise includes three drugs with survival benefit: MabThera (non-Hodgkin's lymphoma), Xeloda (colorectal cancer, breast cancer), and Herceptin (breast cancer), It also includes NeoRecormon (anaemia in various cancer settings), Roferon-A (leukaemia, Kaposi's sarcoma, malignant melan
Contact: Rina Amin